Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of BL-B01D1 in Metastatic or Unresectable NSCLC and Other Solid Tumors
jRCT2031250045Phase 1Recruiting
- Sponsor
- SystImmune Inc.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), breast cancer, esophageal cancer and 4 more (2 cohorts), sponsored by SystImmune Inc. Primary endpoints: Safety and tolerability of BL-B01D1, Maximum tolerated dose (MTD) and 2 more. Started Jul 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)breast canceresophageal cancersmall cell lung cancer (SCLC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on jRCT2031250045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250045.